Immunopharmacologic bases of immunotherapy. NLM AIDSLINE Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Immunopharmacologic bases of immunotherapy.

Clin Physiol Biochem. 1985;3(2-3):111-9. Unique Identifier : AIDSLINE MED/85229186
Hadden JW; Keskiner Merriam L

Abstract: Secondary immune deficiency generally involves more profound defects in cellular than humoral immunity. This type of immune deficiency occurs in acquired immunodeficiency syndrome (AIDS), cancer, malnutrition, aging and following immunosuppressive therapy. Immunorestorative therapies were developed for use in the immunotherapy of cancer. Their experimental use in cancer and other diseases such as infections and autoimmunity has demonstrated their safety and their capacity to improve host responses to disease particularly when the host is immunocompromised. Biologicals such as the thymic hormones and interferon have been intensively studied and are briefly reviewed in this paper. Chemically defined drugs such as levamisole, isoprinosine, azimexon, and muramyl dipeptides have also been extensively analyzed and the action of certain purine-related compounds are discussed to exemplify their immunopharmacologic features. The combined uses of biologicals and drugs are suggested to improve the efficiency of immunotherapy.
Keywords: Human Hypoxanthines/THERAPEUTIC USE Immunologic Deficiency Syndromes/*THERAPY *Immunotherapy Interferons/THERAPEUTIC USE Interleukin-2/ADMINISTRATION & DOSAGE Isoprinosine/THERAPEUTIC USE Purines/THERAPEUTIC USE Thymosin/ANALOGS & DERIVATIVES/THERAPEUTIC USE Thymus Extracts/THERAPEUTIC USE Thymus Hormones/THERAPEUTIC USE Transfer Factor/THERAPEUTIC USE JOURNAL ARTICLE REVIEW

KWDhumanhypoxanthines/therapeuticuseimmunologicdeficiencysyndromes/KWDtherapy
851030
M85A0114

Copyright © 1985 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1985. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1985. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .